Patents by Inventor Masako Doi
Masako Doi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210345602Abstract: An object of the present invention is to provide a substance capable of effectively suppressing the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid, and less likely to adversely affect, when administered in vivo to a mammal, the body of the mammal, and a mammalian cell preservation liquid containing such a substance, and the like. Use of a liquid containing acarbose or a salt thereof and/or stachyose or a salt thereof for preserving a mammalian cell can effectively suppress the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid. Further, the mammalian cell preserved in the liquid can be directly administered in vivo to a mammal, without being transferred into a new transplantation liquid.Type: ApplicationFiled: September 24, 2019Publication date: November 11, 2021Applicant: Otsuka Pharmaceutical Factory, IncInventors: Chikage SHIRAKAWA, Masuhiro NISHIMURA, Masako DOI
-
Patent number: 10945427Abstract: The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days).Type: GrantFiled: June 18, 2014Date of Patent: March 16, 2021Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Masuhiro Nishimura, Tamaki Wada, Chikage Shirakawa, Masako Doi
-
Patent number: 10265346Abstract: A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells.Type: GrantFiled: May 2, 2013Date of Patent: April 23, 2019Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Tamaki Wada, Masako Doi, Takeshi Kikuchi, Eiji Kobayashi
-
Patent number: 10087421Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.Type: GrantFiled: November 9, 2011Date of Patent: October 2, 2018Assignees: OTSUKA PHARMACEUTICAL FACTORY, INC., JICHI MEDICAL UNIVERSITYInventors: Eiji Kobayashi, Tamaki Wada, Yasutaka Fujita, Norihiro Yoshinaga, Masako Doi, Yasuhiro Fujimoto, Takumi Teratani
-
Patent number: 9693982Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.Type: GrantFiled: May 27, 2014Date of Patent: July 4, 2017Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Masako Doi, Masuhiro Nishimura, Nozomi Tamura
-
Patent number: 9498500Abstract: Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %.Type: GrantFiled: April 21, 2015Date of Patent: November 22, 2016Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Eiji Kobayashi, Tamaki Wada, Masako Doi
-
Publication number: 20160120170Abstract: The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days).Type: ApplicationFiled: June 18, 2014Publication date: May 5, 2016Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Masuhiro NISHIMURA, Tamaki WADA, Chikage SHIRAKAWA, Masako DOI
-
Publication number: 20150224145Abstract: Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %.Type: ApplicationFiled: April 21, 2015Publication date: August 13, 2015Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Eiji KOBAYASHI, Tamaki Wada, Masako Doi
-
Patent number: 9060979Abstract: An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof.Type: GrantFiled: October 10, 2007Date of Patent: June 23, 2015Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventor: Masako Doi
-
Patent number: 9040300Abstract: Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %.Type: GrantFiled: September 24, 2013Date of Patent: May 26, 2015Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Eiji Kobayashi, Tamaki Wada, Masako Doi
-
Publication number: 20150118196Abstract: A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells.Type: ApplicationFiled: May 2, 2013Publication date: April 30, 2015Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Tamaki Wada, Masako Doi, Takeshi Kikuchi, Eiji Kobayashi
-
Publication number: 20140309306Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.Type: ApplicationFiled: May 27, 2014Publication date: October 16, 2014Inventors: Masako DOI, Masuhiro NISHIMURA, Nozomi TAMURA
-
Publication number: 20140093961Abstract: Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v)%.Type: ApplicationFiled: September 24, 2013Publication date: April 3, 2014Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Eiji KOBAYASHI, Tamaki WADA, Masako DOI
-
Publication number: 20130260461Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.Type: ApplicationFiled: November 9, 2011Publication date: October 3, 2013Applicants: JICHI MEDICAL UNIVERSITY, OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Eiji Kobayashi, Tamaki Wada, Yasutaka Fujita, Norihiro Yoshinaga, Masako Doi, Yasuhiro Fujimoto, Takumi Teratani
-
Publication number: 20130059913Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.Type: ApplicationFiled: March 31, 2011Publication date: March 7, 2013Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Masako Doi, Masuhiro Nishimura, Nozomi Tamura
-
Patent number: 8273717Abstract: An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.Type: GrantFiled: February 5, 2004Date of Patent: September 25, 2012Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Ippei Yamaoka, Yasuhiro Mitsumoto, Masako Doi, Tetsuya Fukunaga, Mitsuo Nakayama
-
Publication number: 20100197787Abstract: Disclosed is a composition for use in the prevention of a hypoglycemic condition, which comprises at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative of the amino acid or salt as an active ingredient. The composition can promote the uptake of a saccharide into a brain cell to thereby prevent a hypoglycemic condition.Type: ApplicationFiled: September 29, 2006Publication date: August 5, 2010Inventors: Masako Doi, Ippei Yamaoka
-
Publication number: 20100105774Abstract: An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof.Type: ApplicationFiled: October 10, 2007Publication date: April 29, 2010Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventor: Masako Doi
-
Patent number: 7259155Abstract: The present invention provides a phosphonic acid diester compound represented by General Formula wherein R1, R2, R3 and R4 are the same or different, and represent hydrogen, halogen, lower alkyl or lower alkoxy; R5 is phenyl having on the phenyl ring 1–3 substituents selected from the group consisting of lower alkyl, halogen-substituted lower alkyl, lower alkoxy, halogen-substituted lower alkoxy, phenoxy, benzyloxy, hydroxyl, halogen, nitro, lower alkylthio, di(lower alkyl)amino, lower alkanolyamino, pyrrolidinyl and phenyl, or the like, provided that R5 is not mono(lower alkoxy)pheny; and R6 is lower alkyl; and an ACAT-1 inhibitor containing the compound as an active ingredient.Type: GrantFiled: May 5, 2004Date of Patent: August 21, 2007Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Yasuhiro Sakai, Kazuyoshi Miyata, Takahiro Tomoyasu, Akiyoshi Kuroda, Yasuhide Inoue, Akifumi Hagi, Shinya Miki, Norihiro Yoshinaga, Masako Doi, Yoshihiko Tsuda, Seiichirou Kanou
-
Publication number: 20060116426Abstract: An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.Type: ApplicationFiled: February 5, 2004Publication date: June 1, 2006Inventors: Ippei Yamaoka, Yasuhiro Mitsumoto, Masako Doi, Tetsuya Fukunaga, Mitsuo Nakayama